150 related articles for article (PubMed ID: 36351596)
21. Re: "Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in
Smulever A; Barrio Lower Daniele S; Damiano G; Pitoia F
Thyroid; 2020 Aug; 30(8):1224-1225. PubMed ID: 32397830
[No Abstract] [Full Text] [Related]
22. Immunotherapy in anaplastic thyroid cancer: Case series.
Shih SR; Chen KH; Lin KY; Yang PC; Chen KY; Wang CW; Chen CN; Lin CF; Lin CC
J Formos Med Assoc; 2022 Jun; 121(6):1167-1173. PubMed ID: 35031200
[TBL] [Abstract][Full Text] [Related]
23. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
Jeon MJ; Chun SM; Kim D; Kwon H; Jang EK; Kim TY; Kim WB; Shong YK; Jang SJ; Song DE; Kim WG
Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298
[TBL] [Abstract][Full Text] [Related]
24. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
Subbiah V; Kreitman RJ; Wainberg ZA; Cho JY; Schellens JHM; Soria JC; Wen PY; Zielinski C; Cabanillas ME; Urbanowitz G; Mookerjee B; Wang D; Rangwala F; Keam B
J Clin Oncol; 2018 Jan; 36(1):7-13. PubMed ID: 29072975
[TBL] [Abstract][Full Text] [Related]
25. Primary squamous cell carcinoma of thyroid with a novel BRAF mutation and High PDL-1 expression: A case report with treatment implications and review of literature.
Torrez M; Braunberger RC; Yilmaz E; Agarwal S
Pathol Res Pract; 2020 Oct; 216(10):153146. PubMed ID: 32853962
[TBL] [Abstract][Full Text] [Related]
26. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
Fallahi P; Ferrari SM; La Motta C; Materazzi G; Bocci G; Da Settimo F; Miccoli P; Antonelli A
Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966
[TBL] [Abstract][Full Text] [Related]
27. Histological features of BRAF V600E-mutant anaplastic thyroid carcinoma.
Chen TY; Lorch JH; Wong KS; Barletta JA
Histopathology; 2020 Aug; 77(2):314-320. PubMed ID: 32428249
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in anaplastic thyroid cancer management.
Hamidi S; Maniakas A
Curr Opin Endocrinol Diabetes Obes; 2023 Oct; 30(5):259-264. PubMed ID: 37410453
[TBL] [Abstract][Full Text] [Related]
29. Advances in targeted therapy for anaplastic thyroid carcinoma.
Qian C; Jiang L; Xu S; Wang J; Tan Z; Xin Y; Ge M
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 50(6):685-693. PubMed ID: 35347921
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant dabrafenib and trametinib for functional organ preservation in recurrent BRAF V600E-mutated papillary thyroid cancer.
Farlow JL; McCrary HC; Sipos JA; Phay JE; Konda B; Agrawal A
Oral Oncol; 2023 Dec; 147():106625. PubMed ID: 37948895
[TBL] [Abstract][Full Text] [Related]
31. Dabrafenib plus trametinib treatment in patients with anaplastic thyroid carcinoma: an Argentinian experience.
Bueno F; Smulever A; Califano I; Guerra J; Del Grecco A; Carrera JM; Giglio R; Rizzo M; Lingua A; Voogd A; Negueruela MDC; Abelleira E; Pitoia F
Endocrine; 2023 Apr; 80(1):134-141. PubMed ID: 36617605
[TBL] [Abstract][Full Text] [Related]
32. BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma.
Lim AM; Taylor GR; Fellowes A; Cameron L; Lee B; Hicks RJ; McArthur GA; Angel C; Solomon B; Rischin D
J Natl Compr Canc Netw; 2016 Mar; 14(3):249-54. PubMed ID: 26957611
[TBL] [Abstract][Full Text] [Related]
33. [Anaplastic thyroid carcinoma : new therapeutic approaches].
Stamatiou A; Herrera-Gómez RG; Szturz P; Bisig B; Romano E; Sykiotis G; Gorostidi F; La Rosa S; Kopp P; Cristina V
Rev Med Suisse; 2021 May; 17(739):962-966. PubMed ID: 34009754
[TBL] [Abstract][Full Text] [Related]
34. Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers.
Knauf JA; Luckett KA; Chen KY; Voza F; Socci ND; Ghossein R; Fagin JA
J Clin Invest; 2018 Aug; 128(9):4086-4097. PubMed ID: 29990309
[TBL] [Abstract][Full Text] [Related]
35. Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study.
da Silva TN; Rodrigues R; Saramago A; Pires C; Rito M; Horta M; Martins C; Leite V; Cavaco BM
Eur J Endocrinol; 2023 Jan; 188(1):. PubMed ID: 36651156
[TBL] [Abstract][Full Text] [Related]
36. Metastatic-prone telomerase reverse transcriptase (TERT) promoter and v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutated tall cell variant of papillary thyroid carcinoma arising in ectopic thyroid tissue: A case report.
Stenman A; Koman A; Ihre-Lundgren C; Juhlin CC
Medicine (Baltimore); 2021 Jan; 100(2):e24237. PubMed ID: 33466206
[TBL] [Abstract][Full Text] [Related]
37. Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells.
Kurata K; Onoda N; Noda S; Kashiwagi S; Asano Y; Hirakawa K; Ohira M
Int J Oncol; 2016 Dec; 49(6):2303-2308. PubMed ID: 27748799
[TBL] [Abstract][Full Text] [Related]
38. Evaluating new treatments for anaplastic thyroid cancer.
Coca-Pelaz A; Rodrigo JP; Lopez F; Shah JP; Silver CE; Al Ghuzlan A; Menke-van der Houven van Oordt CW; Smallridge RC; Shaha AR; Angelos P; Mendenhall WM; Piazza C; Olsen KD; Corry J; Tufano RP; Sanabria A; Nuyts S; Nathan CA; Vander Poorten V; Dias FL; Suarez C; Saba NF; de Graaf P; Williams MD; Rinaldo A; Ferlito A
Expert Rev Anticancer Ther; 2022 Nov; 22(11):1239-1247. PubMed ID: 36283091
[TBL] [Abstract][Full Text] [Related]
39. Rare Manifestations of Anaplastic Thyroid Carcinoma: the Role of BRAF Mutation Analysis.
Song YS; Jung CK; Jung KC; Park YJ; Won JK
J Korean Med Sci; 2017 Oct; 32(10):1721-1726. PubMed ID: 28875621
[TBL] [Abstract][Full Text] [Related]
40. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer.
Santarpia L; El-Naggar AK; Cote GJ; Myers JN; Sherman SI
J Clin Endocrinol Metab; 2008 Jan; 93(1):278-84. PubMed ID: 17989125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
